New device aims to smooth wrinkles safely in all skin tones

NCT ID NCT07224880

Recruiting now Symptom relief Sponsor: Cytrellis Biosystems, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a device called Ellacor that uses tiny needles to remove small cores of skin, aiming to reduce wrinkles and tighten loose skin on the face and belly. It includes people with a wide range of skin types (I to VI) and those taking GLP-1 drugs like Ozempic for weight loss. The main goal is to see if the device is safe and what changes happen in treated skin over 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ellacor micro-coring device
What this could lead to: If successful, this could show that the Ellacor device is safe and effective for reducing wrinkles and skin looseness in a wide range of skin types, including people taking GLP-1 medications.
What could go wrong: This is a very small early study with only 10 participants, so results may not apply to everyone. It focuses on safety and skin changes, not a cure for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENE EXPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutis laxa Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENE EXPRESSION GLP1 AGONIST SKIN LAXITY

Contacts and locations

Locations

Tri Valley Plastic Surgery
RECRUITING

Dublin, California, 94568, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.